Non-opioid Pain Patch Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The Non-opioid Pain Patch market is expected to register a CAGR of 3.0% during the forecast period, 2022-2027.

The COVID-19 pandemic has impacted the healthcare systems across the world. The health agencies are engaged in containing coronavirus transmission through lockdown norms and have deferred most of the elective and non-urgent surgeries globally. According to the study titled "Pain Management during the COVID-19 Pandemic" published in Pain and Therapy in December 2020, opioid overuse, surgical overuse, and a failure to provide education or advice are examples of general, pre-existing problems that have been exacerbated as a result of the COVID-19 pandemic. As a result, the use of non-opioid pain relievers has increased. For COVID-19 patients, newly prescribed oral NSAIDs may only be used intermittently for a very short period. Thus, the Non-Opioid pain patch market significantly impacted COVID-19.

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The global incidence of cancer is high. As per the GLOBOCAN 2020 report, the incidence of new cancer cases accounted for 19.3 globally and these cases are expected to increase and reach up to 30.2 million by 2040. Thus, the high incidence of cancer may increase the demand for cancer pain management drugs and devices, thereby boosting the market.

Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting, an underlying disease like pancreatitis, spine disease, arthritis, or autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. For instance, National Spinal Cord Injury Statistical Center (NSCISC) 2021 datasheet has accounted the annual incidence of spinal cord injuries at 60 cases per million. There are numerous risk factors for chronic pain. Non-opioid patches are preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches, and also the drugs are released over a long period, therefore, helping in managing the pain for a longer duration and considered a valuable driver for the Non-opioid Pain Patch market.

Meanwhile, a few other players are conducting extensive R&D by collaborating with educational institutions to introduce new non-narcotic pain patches. For Instance, in July 2020, The United States Food and Drug Administration approved an 8% capsaicin patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. The patch is a non-opioid, non-systemic, and topical pain treatment that is the only one on the market that delivers prescription-strength capsaicin directly into the patient's skin.

However, the availability of alternative treatments and the low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of the non-opioid pain patch market.

Scope of the Report

As per the scope of the report, Non-opioids pain patches are primarily used for pain relief. These patches release their medicine content through the skin surface and block the pain signal transmission. The Non-opioid Pain Patch market is segmented by Patch Type (Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, and Others), Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Others), and Geography Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Lidocaine patches are considered the most commonly available patch for the treatment of chronic and acute pain. The factors such as the rise in prevalence of pain and product launch by the key market players boost the segment growth.

Moreover, the data published in October 2021 by World Health Organization (WHO) reported that the pace of population aging is much faster than in the past and by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. The high incidence of chronic pain among Americans and the growing geriatric population are expected to increase the demand for pain management devices and drugs over the forecast period. Thus, rising chronic pain cases and the widespread availability of lidocaine pain relief patches are expected to drive the segment.

Increasing product launches by key market players are anticipated to boost the market. For instance, in August 2020, Amneal Pharmaceuticals, Inc. received Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (FDA) for a generic version of Lidocaine Patch 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for the treatment of post-herpetic neuralgia.

Furthermore, the increasing burden of diseases, along with the safety profile and efficacy associated with lidocaine patches, are expected to drive the growth of the Non-opioid Pain Patch market during the forecast period.

To understand key trends, Download Sample Report